• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    EdgarAgents Debuts EA34 Plugin at Centri Capital Conference to Simplify and Expedite Financial Filing Process for Mid-to-Microcap Companies

    4/22/25 6:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care
    Get the next $COCH alert in real time by email

    NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- EdgarAgents (EA), a leading provider of simplified and efficient solutions that expedite U.S. Securities and Exchange Commission (SEC®) compliance filings, announces today the availability of EA34 Plugin, the company's newest user-centered technology-enabled solution. EA34 Plugin officially launches at the Centri Capital Conference in New York City at Nasdaq Global Headquarters.

    Powered by the latest inline eXtensible Business Reporting Language (iXBRL) — a global standard to share financial and business data electronically — and EDGAR® technology, EA34 Plugin was tailor-made as a "hybrid-service" financial content management collaboration platform. Its fully supported filing process with automated iXBRL capability streamlines compliance and reporting workflows of 8-Ks, 10-Qs, 10-Ks, 20-Fs and 6-Ks mandated by the Securities Exchange Act of 1934.

    "At EdgarAgents, we simplify and expedite the SEC filing and financial printing process to deliver undeniable speed, precision and value with exemplary client service," said Stephen Bonventre, CEO of EdgarAgents. "EA34 Plugin makes it easy for mid-to-microcap companies to shift between full-support and self-service content management so they can continue to file with confidence as they grow and scale."

    For example, EA34 Plugin eliminates the tedious XBRL tagging process. Through plugin technology users work directly in familiar programs such as Microsoft Word® and Microsoft Excel®. CFOs and their financial reporting teams can collaborate with their advisory working groups easily and securely via Microsoft OneDrive®.

    "EA34 Plugin leverages the ubiquity of Microsoft through plugin technology and eliminates the need for complex SaaS platform implementations," said Bonventre. "We've gone to great lengths to understand customer requirements and pain points across this market segment. These insights led to the development of a specific "hybrid solution" that bridges traditional financial printing and substantial SaaS systems and caters to an underserved customer segment."

    As a structured-content hybrid SaaS/managed-services platform, EA34 Plugin allows users to maintain content control of filing documents and shift time-consuming XBRL tagging to EdgarAgents filing experts who work hand-in-hand with clients behind the scenes. The single-source collaboration model guarantees real-time file synchronization, along with role-based editing controls that enhance accuracy and improve security.

    With hands-on collaboration from the EdgarAgents team of 600+ experts available at the click of a mouse, EA34 Plugin is designed as a user-friendly content management and compliance filing platform that reduces anxiety and stress.

    EdgarAgents will demonstrate the capabilities of EA34 Plugin today at the Centri Capital Conference hosted by advisory firm Centri Business Consulting at the Nasdaq MarketSite in Times Square in New York City. The conference will connect investors with executives from presenting companies in various emerging and rapid-growth sectors, including technology, life sciences and healthcare.

    The conference will feature a variety of panels and speakers that will address topics and concerns facing public companies and private companies eyeing public debuts. Bonventre will host a fireside chat titled "File With Confidence: Simplifying Compliance Reporting with EA34 Plugin" featuring David Wells, CFO of Envoy Medical (NASDAQ:COCH) and Blake Roberts, partner at Centri Business Consulting at 1 p.m., immediately following the lunchtime panel as part of Track Two.

    About EdgarAgents

    EdgarAgents (EA) is a leading regulatory compliance filing agency and financial printer with nearly 500,000 reports filed to SEC, FinCEN and other entities since its inception in 2008. EdgarAgents serves registered asset management companies, public and private companies, beneficial owners, in-house and outside counsel, corporate compliance teams, advisory and accounting teams, private equity and investment banking partners. For more information, please visit EdgarAgents.com.

    MEDIA CONTACT

    Justin Scott

    [email protected]



    Primary Logo

    Get the next $COCH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COCH

    DatePrice TargetRatingAnalyst
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    More analyst ratings

    $COCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patel Mona Chetan bought $3,675 worth of shares (2,500 units at $1.47), increasing direct ownership by 14% to 20,000 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      6/13/25 4:10:30 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Director Patel Mona Chetan bought $14,600 worth of shares (10,000 units at $1.46), increasing direct ownership by 133% to 17,500 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      6/10/25 4:11:23 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Chief Executive Officer Lucas Brent T. was granted 12,907 shares, increasing direct ownership by 6% to 216,485 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      6/9/25 8:58:13 PM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

      Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

      6/24/24 7:29:10 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    SEC Filings

    See more
    • Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Envoy Medical, Inc. (0001840877) (Filer)

      6/3/25 4:00:26 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Envoy Medical, Inc. (0001840877) (Filer)

      5/19/25 8:52:08 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Envoy Medical Inc.

      SCHEDULE 13G/A - Envoy Medical, Inc. (0001840877) (Subject)

      5/15/25 8:59:37 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Life Sciences Investor Forum: Now Available for Online Viewing

      NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad

      6/13/25 8:35:00 AM ET
      $ATNM
      $BPTH
      $COCH
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Envoy Medical to Present at the Life Sciences Virtual Investor Forum June 12th

      WHITE BEAR LAKE, Minn., June 11, 2025 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that Brent Lucas, CEO of Envoy Medical, will present live at the Life Sciences Virtual Investor Frum hosted by VirtualInvestorConferences.com, on June 12th, 2025. DATE: June 12th TIME: 3pm EasternLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th through the 17th This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the da

      6/11/25 8:30:00 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Life Sciences Investor Forum Agenda Announced for June 11th-12th

      NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering co

      6/10/25 2:38:09 PM ET
      $ATNM
      $BPTH
      $COCH
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services

    $COCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patel Mona Chetan bought $3,675 worth of shares (2,500 units at $1.47), increasing direct ownership by 14% to 20,000 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      6/13/25 4:10:30 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Director Patel Mona Chetan bought $14,600 worth of shares (10,000 units at $1.46), increasing direct ownership by 133% to 17,500 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      6/10/25 4:11:23 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Director Brynelsen Charles bought $82,403 worth of shares (50,000 units at $1.65) (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      5/27/25 6:34:31 PM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Financials

    Live finance-specific insights

    See more
    • Envoy Medical Reports on First Quarter 2025 Results

      Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat

      5/1/25 4:30:00 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results

      Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to

      3/31/25 9:15:00 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events

      WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. "The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim® fully implanted cochlear implant ("Acclaim CI"). Second, we continue to make tremendous

      11/14/24 8:38:22 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Leadership Updates

    Live Leadership Updates

    See more
    • Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

      WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently

      6/11/24 8:00:00 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical to Host Fireside Chat Event December 7

      Analyst Hosted Event to Feature Comprehensive Discussion of Envoy Medical's Products, Interviews with Two Study Investigators and Key Opinion Leaders in Cochlear Implants WHITE BEAR LAKE, Minnesota, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will host a fireside chat event on Thursday December 7, 2023 beginning at noon Central Time. The event will be hosted by a covering research analyst and feature interactive Q&A with Brent T. Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer. Additionally, the Company

      12/4/23 8:15:00 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Envoy Medical Inc.

      SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

      11/14/24 8:49:34 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Envoy Medical Inc.

      SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

      11/13/24 4:40:10 PM ET
      $COCH
      Industrial Specialties
      Health Care